GlaxoSmithKline (GSK -0.4%) is playing catch-up to rivals Pfizer (PFE +0.1%), Novartis (NVS...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK -0.4%) is playing catch-up to rivals Pfizer (PFE +0.1%), Novartis (NVS -0.5%) and Sanofi-Aventis (SNY -5.1%) in emerging markets, cutting prices in order to double revenue from China and India by 2015. "There’s absolutely a land grab going on right now," says one Glaxo exec.